<DOC>
	<DOCNO>NCT01249677</DOCNO>
	<brief_summary>Glucose-induced insulin secretion often diminished hyperglycaemic patient type 2 diabetes . The investigator examine , whether chronic basal insulin treatment insulin glargine lead improvement glucose-induced insulin secretion .</brief_summary>
	<brief_title>Chronic Reduction Fasting Glycaemia With Insulin Glargine Improves First Second Phase Insulin Secretion Patients With Type 2 Diabetes</brief_title>
	<detailed_description>14 patient type 2 diabetes previous metformin therapy examine eight week treatment insulin glargine , aim normalize fast glycaemia . Intravenous glucose tolerance test perform without previous adjustment fast glucose level mean 3-hour intravenous insulin infusion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Age 18 75 year , inclusive 2 . BMIrange 2750 kg/mÂ² 3. patient type 2 diabetes present fast hyperglycaemia ( &gt; 126mg/dl ) metformin treatment 1.Preexisting insulin therapy , treatment sulphonylureas , glitazones , 2.glinides , DPP4inhibitors exenatide 3.patients type 1 diabetes 4.Patients investigator site personnel directly affiliate study , immediate family investigator site personnel directly affiliate study . Immediate family define spouse , parent , child , sibling , whether biological legally adopt . 5 . Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure include sterilisation , hormonal intrauterine device , oral contraceptive , sexual abstinence vasectomise partner ) . A male subject sexually active surgically sterilise must inform must either use condom intercourse , ensure partner practice contraception , must refrain sexual intercourse trial 1 month completion trial . This prevent possibility pregnancy spermatocytes potentially damage trial medication . It strongly recommend female partner use highly effective contraception ( Pearl Index &lt; 1 % ) . 6 . Patients participate interventional medical , surgical , pharmaceutical study ( study experimental , drug , medical , surgical treatment give ) within 30 day prior screen . This criterion include drug receive regulatory approval indication time study entry . 7 . Patients alcohol consumption ( &gt; 20 g daily male &gt; 10 g daily female ) 8 . Patients alanine aminotransaminase ( ALT ) great ten time upper limit reference range . 9.Patients undergoing therapy malignancy , basal cell squamous cell skin cancer . 10 . Patients cardiac disease Class III IV , accord New York Heart Association criterion . 11 . Patients history renal transplantation currently receive renal dialysis serum creatinine &gt; 1.8 mg/dL male great equal &gt; 1.5 mg/dL female . 12.Patients know hemoglobinopathy chronic anemia 13.Patients receiving chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 week immediately prior screening . 14 . Patients condition ( include know drug alcohol abuse psychiatric disorder ) preclude follow complete protocol , opinion investigator . 15 . Patients fail satisfy investigator suitability participate reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>first phase insulin secretion</keyword>
	<keyword>beta-cell rest</keyword>
	<keyword>basal insulin</keyword>
</DOC>